Basic Information
PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBq/mL
INJECTION, SOLUTION (RADIOPHARMACEUTICAL)
Regulatory Information
SIN16917P
December 18, 2023
Prescription Only
Therapeutic
INTRAVENOUS
January 24, 2024
May 30, 2025
XV10XX05
Company Information
NOVARTIS (SINGAPORE) PTE LTD
NOVARTIS (SINGAPORE) PTE LTD
Active Ingredients
Strength: 1000 MBq/mL
Detailed Information
Contraindications
**5 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in Section 2 Description and composition – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**3 Indications** Pluvicto® is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibitor and taxane-based chemotherapy.